Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Iraq has been experiencing significant growth in recent years.
Customer preferences: Cancer is a major health concern in Iraq, with a high incidence rate of various types of cancer. As a result, there is a strong demand for oncology drugs in the country. Patients and healthcare providers in Iraq prefer drugs that are effective, affordable, and have minimal side effects.
Trends in the market: The market for oncology drugs in Iraq has been expanding rapidly, driven by several factors. Firstly, the increasing prevalence of cancer in the country has led to a higher demand for cancer treatments. Secondly, the government has been investing in improving the healthcare infrastructure in Iraq, which has led to an increase in the availability of oncology drugs. Thirdly, there has been a growing trend towards personalized medicine in Iraq, which has led to an increase in the use of targeted therapies for cancer treatment.
Local special circumstances: Iraq faces several challenges in the oncology drugs market. One of the major challenges is the lack of adequate healthcare infrastructure in the country, particularly in rural areas. This has led to a lack of access to cancer treatments for many patients. Additionally, the ongoing conflict in the country has disrupted the healthcare system, making it difficult to deliver drugs to patients in certain areas.
Underlying macroeconomic factors: The growth of the oncology drugs market in Iraq is also influenced by macroeconomic factors. Iraq is a resource-rich country with a large oil industry, but it has faced significant economic challenges in recent years due to political instability and the decline in oil prices. As a result, the government has been forced to cut spending on healthcare, which has limited the availability of oncology drugs in some areas. However, the government has also been taking steps to diversify the economy and improve the healthcare system, which could lead to further growth in the oncology drugs market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
